Topical Analgesia Post-Haemorrhoidectomy
Launched by UNIVERSITY OF AUCKLAND, NEW ZEALAND · Feb 18, 2020
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
Study Design: This will be a patient-and-investigator blinded factorial randomised trial with four parallel groups. Participants in all four groups will be instructed to apply cream 3 times a day for 7 days after surgery. A standard analgesia prescription will be provided with laxatives as per routine care. Patients will be provided a questionnaire to complete and return on day 14.
Random Sequence Generation: Computer generated sequence allocating patients to a 1:1:1:1 ratio using permuted block randomisation in blocks of 12.
Allocation Concealment: This randomisation code will be seeded ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥16
- • All patients undergoing excisional haemorrhoidectomy
- Exclusion Criteria:
- • Age \<16,
- • history of chronic pain,
- • drug allergy or idiosyncracies to any actives or excipients in
- • cream,
- • breastfeeding,
- * any medical history which is a contraindication to any of metronidazole, lidocaine, or diltiazem including including:
- • sick sinus syndrome,
- • atrioventricular block,
- • hypotension,
- • heart failure and bradycardia.
- • concomitant medications which are contraindicated to metronidazole, lidocaine or diltiazem.
- • patients already taking diltiazem.
About University Of Auckland, New Zealand
The University of Auckland, located in New Zealand, is a leading research institution committed to advancing knowledge and improving health outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and pharmacology to conduct rigorous studies that address pressing health challenges. The institution is dedicated to ethical research practices and aims to translate findings into meaningful clinical applications, ultimately enhancing patient care and contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Auckland, , New Zealand
Patients applied
Trial Officials
Andrew G Hill, MBChB, MD, EdD, FRACS, FACS
Principal Investigator
Counties Manukau Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials